Structure-based ligand design to overcome CYP inhibition in drug discovery projects

• Cytochrome P450 (CYP) enzymes are key players in xenobiotic metabolism, and inhibition of CYPs can therefore result in unwanted drug-drug interactions. Within drug discovery, CYP inhibition can cause delays in the progression of candidate drugs, or even premature closure of projects. During the past decade, a massive effort in the pharmaceutical industry and academic research has produced a wealth of structural information in the CYP field. In this short review, we will describe how structure-based approaches can be used in the pharmaceutical industry to work away from CYP inhibition, with a focus on the opportunities and challenges. We will show two examples from our own work where structural information on CYP2C9 and CYP3A4 inhibitor complexes have been successfully exploited in ongoing drug discovery projects.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)

Nyckelord

HUMAN CYTOCHROME P4502C9

METABOLISM PREDICTIONS

FUNCTIONAL RELEVANCE

RITONAVIR ANALOGS

3A4

BINDING

INSIGHTS

DOCKING

2D6

P4503A4

Pharmacology & Pharmacy

ATES OF AMERICA

V107

P18422

Publikations- och innehållstyp

ref (ämneskategori)

for (ämneskategori)